News Browse all news Symrise reports solid H1 2026 performance with accelerating growth momentum in Q2 Corporate | Financial Organic sales growth accelerated to 4.5% in Q2 2026 (2.0% in H1 2026) Adjusted EBITDA of 553 million and 21.8% adjusted EBITDA margin Adjusted Business Free Cash Flow margin up 450 bps to 13.7% of sales Planned acquisition of Floral Concept will strengthen position in Premium Naturals Full year 2026 outlook reaffirmed Facts & figures Symrise AG share price 89.30 0.20 (0.22%) A case for investment Corporate Report 2025 Events Browse all events Financial Sep 8, 2026 Global Consumer Staples Conference, Boston (Barclays) Add to calendar Financial Sep 9, 2026 Roadshow, New York Add to calendar Financial Sep 21, 2026 German Corporate Conference, Munich (Berenberg/Goldman & Sachs) Add to calendar Financial Sep 28, 2026 Pre-Close Aide-Mmoire Q3 2026 Add to calendar Financial Sep 29, 2026 Quiet Period Add to calendar Financial Oct 29, 2026 Quarterly Statement Q3 2026 Add to calendar Your career at Symrise create with us

Tc dng lm trng da ca L-Glutathione c c thng qua c ch tng cng to sc t melanin sng v ngn nga hc t melanin bng cch can thip vo qu trnh chuyn ha, ngn nga hot ng ca enzyme tyrosinase, gip da trng dn v u mu hn
Research and Ongoing Scientific Interest Scientific interest in peptide compounds continues to evolve as new studies are conducted and published
highlighting its potential development as neuroprotective agent
Gene-induced chondrogenesis of primary mesenchymal stem cells in vitro